Juvaris completes $25M close of series B

Adjuvant vaccines developer Juvaris BioTherapeutics has completed the first close of a Series B round. The Burlingame, CA-based company says it will use the capital to advance its technology platform and carry its lead adjuvant, JVRS-100, into midstage clinical development for seasonal and pandemic flu.

The financing of up to $25 million was funded by SV Life Sciences and Kleiner Perkins Caufield & Byers (KPCB). SV Life Sciences' managing partner Michael Ross will join Juvaris Board of Directors. "Mike's highly successful drug development experience at Genentech and track record of building strong biotech companies at SVLS will be of critical ongoing value to Juvaris," said CEO Grant Pickering.

- here's the Juvaris release

Suggested Articles

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.